• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Digital Therapeutics and Their Impact on Healthcare

Share:

July 29, 2019

Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory?approved, to treat medical conditions as prescribed therapeutic interventions.There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards.

DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions.

This report provides an overview of current marketed and pipeline DTx products within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China).

Scope
– This report combines primary research from a cross-specialty panel of experts with in-house analyst expertise to provide an assessment of the development landscape.
– Components of the slide deck include primary and secondary research:
– Quotes from 10 key opinion leaders (7 US, 1 EU, 2 Japan) and 2 payers (1 US and 1 UK)
– Summary of DTx product definitions and classifications
– Overview of key DTx marketed products and key pipeline DTx products
– Trends in DTx market
– Call-outs of key information and details
– Insight from GlobalData’s specialist healthcare analysts.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Reasons to buy
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global DTx market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DTx market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Date: July 29, 2019

Source: PR Newswire

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • New Healthcare Trends Have Investors Looking at 4 StocksNew Healthcare Trends Have Investors Looking at 4 Stocks
  • Corrona Acquires Healthivibe, Expanding Its Presence in Patient ExperienceCorrona Acquires Healthivibe, Expanding Its Presence in Patient Experience
  • BioAgilytix Announces Acquisition of Boston-Based Clinical Research Organization Cambridge BiomedicalBioAgilytix Announces Acquisition of Boston-Based Clinical Research Organization Cambridge Biomedical
  • Jefferson Health Deploys EHR-Integrated COVID-19 Chatbot for Screening and IntakeJefferson Health Deploys EHR-Integrated COVID-19 Chatbot for Screening and Intake
  • Blue Shield of CA Launches Digital “Neighborhood Health Dashboard” for PublicBlue Shield of CA Launches Digital “Neighborhood Health Dashboard” for Public
  • Bruker Announces Agreement to Acquire Majority in Infectious Disease-focused Molecular Diagnostics (MDx) Company Hain Lifescience GmbHBruker Announces Agreement to Acquire Majority in Infectious Disease-focused Molecular Diagnostics (MDx) Company Hain Lifescience GmbH
  • Ada Health Partners with Novartis to Work on Diagnosis for Immunological DiseasesAda Health Partners with Novartis to Work on Diagnosis for Immunological Diseases
  • FDA Clears Circadia Health’s Respiratory Monitoring Platform ShareFDA Clears Circadia Health’s Respiratory Monitoring Platform Share

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications